Adderal XR Claims Construction: Shire, Impax & Barr
Introduction Barr and Impax seek to launch generic versions of Shire Lab’s ADHD drug Adderal XR®. Shire sued Barr in [...]
Adderall XR: Shire Shares Rise on Settlement With Barr
Bloomberg By Etain Lavelle – Aug 15, 2006 Shire Plc shares rose after the company settled a patent lawsuit with [...]
Neurontin 1: Interim Status Report
Introduction. Neurontin, is Pfizer’s (formerly Warner-Lambert’s) $ 2 billion a year FDA-approved epilepsy medication. Warner Lambert’s first generation patents have [...]
Neurontin 2: Generic Competition likely in September ‘02
The battle over Neurontin (whose active ingredient is gabapentin) is heating up: A hearing is scheduled for Monday, September 9, [...]
Paxil 1: Glaxo’s Patents Appear Safe Until at least 2006
January 31, 2002 INTRODUCTION Although there has been one $8 million verdict in a personal injury case involving Paxil, it [...]
Paxil 2: Invalidation of UK patents will not impact US cases
August 14, 2002 Introduction. On July 12, 2002, in a revocation proceeding brought by BASF, the British patent court invalidated [...]
Plavix® Should Survive Generic Attack until 2011
December 27, 2002 This article is based on the patents, the prosecution histories and the preliminary pleadings filed with the [...]
Related Case Type
